GEMTESA: payments to doctors
Payments that named GEMTESA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $8.2M
- Providers
- 44,887
- Transactions
- 237,061
- Average per transaction
- $35
The per-transaction average — $35 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 44,887 providers the average total is $184, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Sumitomo Pharma America, Inc. | $5,598,029 | 67.9% |
| Urovant Sciences Inc | $2,226,302 | 27.0% |
| Sunovion Pharmaceuticals Inc. | $424,652 | 5.1% |